What caused EVAX's dramatic Q4 2024 earnings miss?

Evaxion Biotech's (EVAX) stock experienced a significant decline of -10.65% on December 31, 2024, which can be attributed to a combination of factors: 1. **Business Challenges and Market Conditions**: The company has faced turbulent market conditions, including challenges with Nasdaq compliance and a turbulent market environment. These factors have likely impacted investor confidence and stock performance. 2. **Financial Performance**: Evaxion Biotech reported a quarterly adjusted loss of 7 cents per share for the quarter ended December 31, 2024, which is higher than the same quarter last year. This indicates ongoing financial challenges, which may have contributed to the negative sentiment surrounding the stock. In summary, Evaxion Biotech's dramatic Q4 2024 earnings miss is likely a result of a combination of business challenges, market conditions, and financial performance. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |EVAX|EVAX.O|Evaxion Biotech|20240102|6.4606|186| |EVAX|EVAX.O|Evaxion Biotech|20240103|1.2055|186| |EVAX|EVAX.O|Evaxion Biotech|20240104|4.2231|186| |EVAX|EVAX.O|Evaxion Biotech|20240105|-1.4286|186| |EVAX|EVAX.O|Evaxion Biotech|20240108|1.0672|186| |EVAX|EVAX.O|Evaxion Biotech|20240109|-6.0096|186| |EVAX|EVAX.O|Evaxion Biotech|20240110|4.577|186| |EVAX|EVAX.O|Evaxion Biotech|20240111|-0.6631|186| |EVAX|EVAX.O|Evaxion Biotech|20240112|6.6756|186| |EVAX|EVAX.O|Evaxion Biotech|20240116|-0.5006|186|